Patents by Inventor Koichi TAZAKI

Koichi TAZAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION FOR USE IN TREATING AML AND METHOD OF TREATING AML IN A SUBJECT IN NEED THEREOF
    Publication number: 20180303812
    Abstract: The present invention provides a pharmaceutical composition for use in treating acute myeloid leukemia (AML) and a method of treating AML in a patient in need thereof. The present invention also provides a method for predicting the sensitivity to the treatment in the patient using gene expression signature.
    Type: Application
    Filed: October 21, 2016
    Publication date: October 25, 2018
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Kenji NAKAMARU, Koichi TAZAKI, Takahiko SEKI, Ngai-chiu Archie TSE, Michael ANDREEFF, Jo ISHIZAWA
  • ALGORITHMS FOR GENE SIGNATURE-BASED PREDICTOR OF SENSITIVITY TO MDM2 INHIBITORS
    Publication number: 20170283885
    Abstract: Provided are gene signatures that are predictive of the sensitivity of a cancer or tumor to an MDM2i or an antagonist of the MDM2-p53 interaction. Differentially expressed genes in the provided gene signatures serve as biomarkers for determining and assessing the sensitivity of cancer and tumor samples to treatment or therapy with an MDM2i. Also provided are methods of determining MDM2i sensitivity of a test sample such as different cancer and tumor types and subtypes, based on the expression of genes in the MDM2i sensitive gene signatures in reference samples and the test sample even if all of the MDM2i sensitivities of the reference samples are unknown, and treating individuals with an MDM2i if their cancers are determined to be MDM2i-sensitive, based on the practice of the described methods. TP53 gene and p53 protein status can also be determined for the samples undergoing analysis for MDM2i sensitivity.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 5, 2017
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ngai-chiu Archie TSE, Kenji NAKAMARU, Koichi TAZAKI, Kenji WATANABE, Takahiko SEKI
  • GENE SIGNATURES ASSOCIATED WITH SENSITIVITY TO MDM2 INHIBITORS
    Publication number: 20160333419
    Abstract: Gene signatures that are predictive of the sensitivity of a cancer or tumor to an MDM2i or an antagonist of the MDM2-p53 interaction. Differentially expressed genes in the provided gene signatures serve as biomarkers assessing the sensitivity of cancer and tumor samples to treatment or therapy with an MDM2i. Also provided are methods of determining MDM2i sensitivity of different cancer and tumor types and subtypes, based on the expression of genes in the MDM2i sensitive gene signatures, and treating individuals with an MDM2i if their cancers are determined to be MDM2i-sensitive. TP53 gene and p53 protein status can be determined for the samples undergoing analysis for MDM2i sensitivity. Methods, platforms, kits, reagents, and compositions of the invention provide advantageous approaches and tools for personalized or individualized treatments of cancer patients whose cancers exhibit sensitivity to MDM2 inhibitors.
    Type: Application
    Filed: January 13, 2015
    Publication date: November 17, 2016
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ngai-chiu Archie TSE, Kenji NAKAMARU, Koichi TAZAKI, Kenji WATANABE, Takahiko SEKI